David Krempa - 24 Aug 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Chief Business Officer
Issuer ticker: ETON
Reported as of: 24 Aug 2026
Net transaction value: -$1,626,750
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:19:33 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith Matthews

Key filing fact

David Krempa filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 24 Aug 2026.

Key facts

This page summarizes David Krempa's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Aug 2026, 17:19.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: -$1,626,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968254 Primary reporting owner

Krempa David

Relationship: Chief Business Officer
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ Judith Matthews
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETON transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,000
Change %: +68%
Price: $7.31^*
Shares after: 62,025
Date: 24 Aug 2026
Ownership: Direct

ETON transaction

Common Stock

Sale

Transaction value: $1,626,750
Shares: -25,000
Change %: -40%
Price: $65.07
Shares after: 37,025
Date: 24 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Employee Stock Option

Options Exercise

Transaction value
Shares: -25,000
Change %: -26%
Price: $0.000000^*
Shares after: 70,000
Date: 24 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $7.31
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Footnote F2

The shares were sold in multiple trades at prices ranging from $64.88 to $65.57. The price reported above reflects the weighted average sales price.

Footnote F3

The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-20-2019) until fully vested.

SEC remarks

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.